• Medicine- Regonat
  • API- Regorafenib
  • Packaging- 28 Tablets
  • Strength- 40 mg
  • Manufactured- Natco Pharma
Get an Enquiry


A multi-kinase inhibitor, Regorafenib Tablet, is indicated for the treatment of:

  • Metastatic Colorectal Cancer
  • Advanced Hepatocellular Carcinoma
  • Also, Advanced Gastoinstenstial Stromal Tumors

Dosage and Side Effects

Oral administration of Regorafenib should be done at the same time every day, following a low-fat diet. The 40 mg pills of Regorafenib should be swallowed whole with water. It is not recommended to split, chew, break, or open tablets.

Weakness, exhaustion, lack of appetite, mouth ulcers, desquamation on the palm, weight loss, and changes in voice quality are among the most frequent side responses.

Additionally, extreme adverse effects from regorafenib include high blood pressure, skin peeling, and severe bleeding.

Warning and Precautions

  • It is not advised for women to take 40 mg of regorafenib when they are pregnant.

  • The use of Regorafenib tablets may be the cause of hypersensitivity and bleeding.

  • Regorafenib may cause dermatologic toxicity in certain patients, therefore use extreme caution when taking it and speak with your doctor.

  • If someone is on a Regorafenib tablet, wait to get vaccinated until after you have received approval from your doctor.


What is Metastatic Colorectal Cancer?

Metastatic Colorectal Cancer refers to cancer that has spread from the colon or rectum to other parts of the body.

Is Regorafenib considered a chemotherapy drug?

Regorafenib is a prescribed anticancer medication used after prior treatment with specific chemotherapy drugs.

Has Regorafenib received FDA approval?

Yes, Regorafenib has been approved by the FDA.

What are the components in Regorafenib?

The active ingredient in Regorafenib is Regorafenib itself, accompanied by inactive elements like cellulose microcrystalline, croscarmellose sodium, magnesium stearate, povidone, and colloidal silicon dioxide.